A unique laboratory test combining biomarkers and a liver stiffness measurement by FibroScan to provide enhanced classification accuracy for patients with chronic hepatitis B or C (with or without co-infection with HIV), or patients with non-alcoholic fatty liver disease (NAFLD).
Features and Benefits
- Enhanced classification accuracy
- First integrated patient report combining the FibroScan liver stiffness measurement and FibroMeter results.
- Non-invasive Assessment of Liver Fibrosis
by Patricia R. Slev, PhD
Scores are algorithmically calculated from values of blood biomarkers, Fibroscan VCTE measurement, and demographic information.
|Measurements Performed by ARUP||Alpha-2-macroglobulin, AST, GGT, prothrombin index|
|Information Provided by Client||Liver stiffness result (in kPa) from the Fibroscan VCTE, patient’s platelet count, age, gender Submit form with order.|
|Calculated Scores and Metavir Classifications||Score ranges from 0 to 1, Metavir classifications range from F0-F4:
Note: This test should not be used in patients younger than 18 years of age.
How to Order
Please contact your hospital or reference laboratory to inquire about pricing, test-request forms, and billing for this test.
Test requires Fibroscan score ( submit form with order)
|Test Name||Liver Fibrosis - FibroMeter Vibration Controlled Transient Elastography (FibroMeter plus FibroScan VCTE)|
Dincsesa E, Yilmaz Y. Diagnostic usefulness of Fibrometer VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenerol Hepatol 2015;27:1149–53.
Loong TC, Wei JL, Leung JC, et al. Application of the combined FibroMeter VCTE algorithm in Chinese patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2017;32(7):1363–69.
Ducancelle A, et al. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases. J Clin Gastroenterol 2017;51(7):639–49.
Degos F, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53:1013–21.
Boursier J, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol 2017;66(6):1158–65.
Boursier J, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J Hepatol 2016;65(3):570–8
Boursier J, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011;106(7):1255-63.
Calès P, et al. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver Int 2014;34(6):907–17.
Calès P, et al. Liver fibrosis diagnosis by blood test and elastography in chronic hepatitis C: agreement or combination? Aliment Pharmacol Ther 2017;45(7):991–1003.
Zarski JP, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012;56:55–62.